好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Mediterranean Diet Impacts Gastrointestinal Symptoms and Modulates Gut Microbiota in People with Parkinson’s Disease
Movement Disorders
P13 - Poster Session 13 (8:00 AM-9:00 AM)
5-001
The aim of this pilot study in individuals with Parkinson’s disease (PD) was to determine 1) whether a Mediterranean diet (MediDiet) intervention is feasible and 2) induces changes in gastrointestinal function, intestinal permeability and fecal microbial communities.
Studies suggests PD is associated with increased intestinal permeability, inflammation, and dysregulated microbiota, yet little is known about how modifying dietary intake impacts PD. Dietary intake of fruits and vegetables that provide fermentable fibers as an energy source for beneficial intestinal bacteria may help maintain intestinal barrier function and decrease gastrointestinal symptoms and inflammation.
A single-arm, 5-week MediDiet intervention was conducted in 8 people with PD (71.4±2.6 years, mean±SEM). Questionnaires were administered to determine changes in diet and gastrointestinal symptoms. Urine and fecal samples were collected at baseline and 5 weeks to assess intestinal permeability (oral sugar probes) and fecal microbial communities (16s rRNA sequencing). Live-in partners of the participants with PD were matched as controls (n=8, 71.3±2.4 years) for baseline urine and fecal samples.
MediDiet scores increased from baseline to week 5 (4.4±0.6 vs. 11.9±0.7; P<0.01 with >10=good adherence). Constipation syndrome scores were decreased after 5 weeks (2.3±0.5 vs. 1.5±0.3; P=0.04 with 1=no discomfort to 7=very severe discomfort). Multiple OTUs from fecal samples were different at baseline and altered after the MediDiet. Proportion of Bilophila, was elevated at baseline (0.6±0.1% vs. 0.2±0.1%; P=0.02) with PD compared to matched controls and decreased after the diet intervention (0.5±0.1%; P<0.01). Proportion of Roseburia was significantly lower with PD (0.6±0.2% vs. 1.6±0.3%; P=0.02) and increased at week 5 (0.9±0.2%; P<0.01). No differences were observed for intestinal permeability at baseline or post-intervention.

Differences in fecal bacterial taxa are prevalent with PD compared to their live-in partners. Short-term MediDiet adherence is feasible with PD and data suggest this diet reduces symptoms of constipation and modulates gut microbiota.
Authors/Disclosures
Carley Rusch (University of Florida)
PRESENTER 		Ms. Rusch has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Shannon Y. Chiu, MD, MSc (Mayo Clinic Arizona) Dr. Chiu has received research support from NIH.
Bhavana U. Patel, DO (Bhavana Patel) The institution of Dr. Patel has received research support from National Institute on Aging. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving as a Question writer with 好色先生.
Adolfo Ramirez Zamora, MD (University of Louisville) Dr. Ramirez Zamora has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medtronic. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevel therapeutics. Dr. Ramirez Zamora has received personal compensation in the range of $0-$499 for serving as a Consultant for NeuroPacs. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Scientific. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iota Inc. Dr. Ramirez Zamora has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Maplight. Dr. Ramirez Zamora has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. The institution of Dr. Ramirez Zamora has received research support from Parkinsons Foundation.
No disclosure on file